Boehringer-Ingelheim

From Wikipedia, the free encyclopedia

This article or section reads like an advertisement.
Please help rewrite this article from a neutral point of view per Wikipedia policy. Mark blatant advertising for speedy deletion with {{db-spam}}. (help, talk)

Boehringer Ingelheim GmbH

Type	Pharmaceuticals/Private
Founded	Germany (1885)
Headquarters	Binger Str. 173 55216 Ingelheim Germany
Key people	Dr Alessandro Banchi, Chairman Dr Andreas Barner, Vice Chairman Professor Marbod Muff, Head of Finance Dr Hans-Jürgen Leuchs, Head of Operations
Industry	Pharmaceuticals
Products	Medicines, ie. Aggrenox, Flomax, Micardis
Revenue	€9.535 billion EUR (2005)
Operating income	€1.923 billion EUR (2005)
Net income	€1.514 billion EUR (2005)
Employees	37,406 (2005)
Slogan	Value through Innovation
Website	http://www.boehringer-ingelheim.com

Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for around 95% of sales. This includes prescription medicines and consumer healthcare products.

1 History
2 Fields of activity
3 Operational and development sites
4 Key product lines
5 External links

[edit] History

The company was founded in 1885 during the Gründerzeit by the German chemist Dr Albert Boehringer. Initially it produced tartaric acid from wine yeast in a small factory in Ingelheim, together with 20 employees. Today, 120 years later, the Boehringer Ingelheim group is one of the world's top 20 pharmaceutical companies. For some years now, Boehringer Ingelheim has been one of the fastest-growing companies in the pharmaceutical industry and one of the world's largest manufacturers of biopharmaceuticals for industrial customers. Boehringer Ingelheim currently has 143 affiliated companies in and outside Germany.

[edit] Fields of activity

Boehringer Ingelheim researches, develops, manufactures and supplies pharmaceuticals and biopharmaceuticals. The primary focus is on Human Pharmaceuticals, including treatments for respiratory, cardiovascular, central nervous system, urological and virological disorders. In addition the research has been intensified into the immune system, metabolic diseases and cancer. Oncology is new among Boehringer Ingelheim’s indication areas.

[edit] Operational and development sites

The company's largest site and corporate headquarters is located in Ingelheim am Rhein near Mainz and Frankfurt, Germany. However, Boehringer Ingelheim is a globally operating company, with almost 150 subsidiaries around the globe. Their main business regions are Europe, North America and Asia.

As of December 2005, the Boehringer Ingelheim group of companies had nearly 37,500 employees worldwide. Of these, around 30% worked in production, 37% in marketing and sales and 16% in research and development. In Germany, Belgium, Brazil, the Netherlands, Switzerland and the United Kingdom, Boehringer Ingelheim has received recognition as one of the best Employers. For example, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For.